Get the Stockscreener App
4.69
35.94%
1.24
After Hours:
4.61
-0.08
-1.71%
Sight Sciences Inc stock is traded at $4.69, with a volume of 1.62M.
It is up +35.94% in the last 24 hours and up +37.13% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$3.45
Open:
$3.9
24h Volume:
1.62M
Relative Volume:
12.26
Market Cap:
$245.60M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-4.114
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
+46.56%
1M Performance:
+37.13%
6M Performance:
+76.32%
1Y Performance:
-21.18%
1-Day Range:
$3.89
$4.80
1-Week Range:
$3.215
$4.80
52-Week Range:
$2.03
$6.08
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
4.69 | 180.67M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
128.54 | 222.13B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
99.24 | 144.89B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
374.42 | 141.17B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.78 | 121.91B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
74.64 | 42.65B | 5.69B | 1.41B | 577.90M | 6.9828 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
How Sight Sciences Inc. stock responds to policy changesTrade Performance Summary & Reliable Price Breakout Signals - Trung tâm Dự báo KTTV quốc gia
Will Sight Sciences Inc. stock outperform international peersMarket Growth Review & Stock Timing and Entry Methods - Trung tâm Dự báo KTTV quốc gia
Is it time to cut losses on Sight Sciences Inc.2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Medicare establishes pricing for Sight Sciences’ TearCare System - Investing.com
Sight Sciences, Inc. Announces Jurisdiction-Wide Pricing for TearCare® Procedure - TradingView
Sight Sciences Announces Medicare Pricing for TearCare® Procedure in Novitas and First Coast Jurisdictions - Quiver Quantitative
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure - The Manila Times
10.4M covered lives: Sight Sciences wins jurisdiction-wide Medicare fee for CPT 0563T with Jan 1, 2025 effective date - Stock Titan
Is Sight Sciences Inc a good long term investmentPortfolio Risk Assessment & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
SGHT: CPT 0563T priced at $1,141.59; 10.4M lives in Novitas/FCSO - Stock Titan
Candlestick signals on Sight Sciences Inc. stock todayJuly 2025 Institutional & Intraday High Probability Alerts - newser.com
3 Promising Penny Stocks With Market Caps Up To $300M - simplywall.st
Why Sight Sciences Inc. stock is trending among retail tradersShare Buyback & AI Enhanced Market Trend Forecasts - newser.com
Sight Sciences price target lowered to $4 from $4.50 at Citi - MSN
Is a relief rally coming for Sight Sciences Inc. holdersWeekly Trend Report & Verified Short-Term Trading Plans - newser.com
Is Sight Sciences Inc. stock a defensive play in 2025Quarterly Profit Report & AI Driven Price Forecasts - newser.com
Can machine learning forecast Sight Sciences Inc. recoveryJobs Report & Daily Momentum Trading Reports - newser.com
Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Cash from operating activities of Sight Sciences, Inc. – BOATS:SGHT - TradingView
What analysts say about Sight Sciences Inc stockStraddle and Strangle Trades & Low Entry Risk Stocks - earlytimes.in
What does recent volatility data suggest for Sight Sciences Inc.July 2025 Breakouts & Safe Capital Growth Tips - newser.com
Sector ETF performance correlation with Sight Sciences Inc.Take Profit & Risk Adjusted Buy/Sell Alerts - newser.com
Does Sight Sciences Inc. qualify in momentum factor screeningQuarterly Performance Summary & Community Verified Watchlist Alerts - newser.com
Live market analysis of Sight Sciences Inc.2025 Support & Resistance & Growth Focused Investment Plans - newser.com
Intraday pattern recognizer results for Sight Sciences Inc.July 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Evp Taylor Brenton sells Sight Sciences (SGHT) shares for $1,991 By Investing.com - Investing.com Canada
Sight Sciences (NASDAQ:SGHT) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
SGHT Form 4: 591-share tax-sale at $3.32–$3.45 range - Stock Titan
Sight Sciences (NASDAQ:SGHT) Given New $4.00 Price Target at Citigroup - Defense World
Citigroup Lowers Sight Sciences (NASDAQ:SGHT) Price Target to $4.00 - MarketBeat
Citigroup Maintains Sight Sciences (SGHT) Neutral Recommendation - MSN
Using AI based signals to follow Sight Sciences Inc.Quarterly Portfolio Report & Target Return Focused Picks - newser.com
How Sight Sciences Inc. stock performs in interest rate cyclesWeekly Market Summary & Low Drawdown Investment Ideas - newser.com
SGHT Form 144: 591 Shares from Restricted Stock Vest on 09/30/2025 - Stock Titan
Chart based analysis of Sight Sciences Inc. trendsQuarterly Portfolio Review & Low Risk High Win Rate Picks - newser.com
Can you recover from losses in Sight Sciences Inc.2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
Using data filters to optimize entry into Sight Sciences Inc.Share Buyback & Consistent Return Strategy Ideas - newser.com
What’s next for Sight Sciences Inc. stock price2025 Risk Factors & Daily Stock Trend Watchlist - newser.com
David Badawi Sells 6,033 Shares of Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
Jeremy Hayden Sells 9,731 Shares of Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
Technical analysis overview for Sight Sciences Inc. stockWeekly Stock Analysis & AI Optimized Trading Strategy Guides - newser.com
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):